Key Details
Price
$4.84Annual ROE
-35.17%Beta
2.62Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 22, 2024Recent annual earnings:
Mar 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with EXAI included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia
On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve the new-drug discovery process with artificial intelligence.
Chris Gibson, Recursion co-founder and CEO, joins 'Squawk Box' to discuss the company's $688 million acquisition of Exscientia, the use of AI in drug discovery, and more.
On Thursday, Exscientia plc EXAI agreed to merge with Recursion Pharmaceuticals Inc. RXRX.
Operational complementarities expected to yield annual synergies of approximately $100 million Operational complementarities expected to yield annual synergies of approximately $100 million
Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal, according to a statement seen by Reuters.
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=87422&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=87392&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , June 25, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
FAQ
- What is the primary business of Exscientia?
- What is the ticker symbol for Exscientia?
- Does Exscientia pay dividends?
- What sector is Exscientia in?
- What industry is Exscientia in?
- What country is Exscientia based in?
- When did Exscientia go public?
- Is Exscientia in the S&P 500?
- Is Exscientia in the NASDAQ 100?
- Is Exscientia in the Dow Jones?
- When was Exscientia's last earnings report?
- When does Exscientia report earnings?
- Should I buy Exscientia stock now?